RET融合陽性パピラリ甲状腺癌の分子病原性と治療の進歩

Yuqing Wei¹, Yan Zhang², Zongjing Zhang³

¹Department of Pathology, The Postgraduate Training Base of Jinzhou Medical University (The 960th Hospital of the PLA Joint Logistic Support Force), Jinan 250031, China; Department of Pathology, The 960th Hospital of the PLA Joint Logistic Support Force, Jinan 250031, China.

Pathology, research and practice

|February 19, 2026

まとめ

RET融合はパピラリ甲状腺がん (PTC) の成長を誘発する. 選択的RET阻害剤は有望ですが,耐性については,効果的な精密治療のためのさらなる研究が必要です.

科学分野:

エンドクリノロジーエンドクリノロジー
腫瘍学腫瘍学
分子生物学は分子生物学である.

背景:

papillary thyroid carcinoma (PTC) は,最も一般的な内分泌の悪性腫瘍である.
RET融合はPTCにおける重要な遺伝的原動力であり,侵入性および不良の予後に関連しています.

研究の目的:

RET融合陽性PTCの分子病原性を体系的に検討する.
RET阻害剤の臨床効果と耐性メカニズムを分析する.

主な方法:

分子病原性および臨床研究に関する文献レビュー.
RETプロトオンコゲン,融合イベント,シグナル伝達経路,および抵抗機構の分析.

主要な成果:

RET融合,特にCCDC6-RETとNCOA4-RETは,持続的な経路活性化につながる.
選択的RET阻害剤 (セルパーカチニブ,プラセチニブ) は,小児および耐火性症例を含む有効性を示しています.
標的上の変異とバイパス活性化は,主要な抵抗メカニズムです.

結論:

RET融合の病原性を理解することは,正確な診断と治療に不可欠です.
RET阻害剤は新しい治療法を提供しており,患者の改善のためにレジスタンスに対処する研究が進行中です.

キーワード:

CCDC6-RET核融合について NCOA4-RETによる核融合によるパピラー性甲状腺がん (Thyroid carcinoma) とは RETの核融合についてです.

さらに関連する動画

07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K

06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.4K

関連する概念動画

02:57

Targeted Cancer Therapies

9.0K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

9.0K

01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

01:27

Tumor Immunotherapy

2.0K

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

2.0K

02:23

Abnormal Proliferation

5.3K

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

5.3K

02:07

Tumor Progression

7.5K

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...